Abstract
Anosmia is common in COVID-19 patients, lasting for weeks or months following recovery. The biological mechanism underlying olfactory deficiency in COVID-19 does not involve direct damage to nasal olfactory neurons, which do not express the proteins required for SARS-CoV-2 infection. A recent study suggested that anosmia results from downregulation of olfactory receptors. We hypothesized that anosmia in COVID-19 may also reflect SARS-CoV-2 infection-driven elevated expression of regulator of G protein signaling 2 (RGS2), a key regulator odorant receptor, thereby silencing their signaling. To test our hypothesis, we analyzed gene expression of nasopharyngeal swabs from SARS-CoV-2 positive patients and non-infected controls (two published RNA-sequencing datasets, 580 individuals). Our analysis found upregulated RGS2 expression in SARS-CoV-2 positive patients (FC=14.5, Padj=1.69e-05 and FC=2.4; Padj=0.001, per dataset). Additionally, RGS2 expression was strongly correlated with PTGS2, IL1B, CXCL8, NAMPT and other inflammation markers with substantial upregulation in early infection. These observations suggest that upregulated expression of RGS2 may underlie anosmia in COVID-19 patients. As a regulator of numerous G-protein coupled receptors, RGS2 may drive further neurological symptoms of COVID-19. Studies are required for clarifying the cellular mechanisms by which SARS-CoV-2 infection drives the upregulation of RGS2 and other genes implicated in inflammation. Insights on these pathways may assist in understanding anosmia and additional neurological symptoms reported in COVID-19 patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data was obtained from the following publicly available Gene Expression Omnibus (GEO) datasets: GSE163151 and GSE152075.
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE163151
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE152075
Abbreviations
- ACE2
- angiotensin-converting enzyme 2
- COVID-19
- coronavirus disease-2019
- CXCL8
- C-X-C motif chemokine ligand 8
- GEO
- gene expression omnibus
- IL1B
- interleukin 1 beta
- NAD
- nicotinamide adenine dinucleotide
- NAMPT
- nicotinamide phosphoribosyltransferase
- NCBI
- National Center for Biotechnology Information
- PTGS2
- prostaglandin-endoperoxide synthase 2
- RGS2
- regulator of G protein signaling 2
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus 2
- TMPRSS2
- transmembrane serine protease 2
